Literature DB >> 19584443

Novel T719P AbetaPP mutation unbalances the relative proportion of amyloid-beta peptides.

Roberta Ghidoni1, Valentina Albertini, Rosanna Squitti, Anna Paterlini, Anna Bruno, Silvia Bernardini, Emanuele Cassetta, Paolo Maria Rossini, Ferdinando Squitieri, Luisa Benussi, Giuliano Binetti.   

Abstract

A novel missense mutation (T719P) in the amyloid-beta protein precursor (AbetaPP) gene was discovered in a 46-year old patient affected by early onset familial Alzheimer's disease. Using surface enhanced laser desorption/ionization mass spectrometry (SELDI-TOF MS), we determined mass profiles of amyloid-beta peptides (Abeta) in cerebrospinal fluid (CSF) of the AbetaPP mutated patient, healthy control subjects (n = 10), and of two subjects carrying mutations in presenilins genes (PS) (i.e., PS1 P117L and PS2 T122R): seven different C-terminally and three N-terminally truncated Abeta peptides were found in CSF. The investigated AbetaPP as well as PS mutations were associated with an overall reduction of Abeta species, except for Abeta(10-40). Interestingly, the AbetaPP T719P mutation unbalanced the relative proportion of Abeta peptides with a reduction of Abeta(1-40) and Abeta(1-42) paralleled by an increase of Abeta(1-38) and Abeta(10-40). Despite the specific neuropeptidomic phenotype associated with the AbetaPP T719P mutation, the enrichment in Abeta(10-40) paralleled by depletion of Abeta(1-42) seems to be a common theme in familial AD. The AbetaPP T719P mutation is of particular interest because it is the only mutation located in close proximity to the AbetaPP epsilon-cleavage site.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19584443     DOI: 10.3233/JAD-2009-1142

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  10 in total

Review 1.  Central and Peripheral Metabolic Defects Contribute to the Pathogenesis of Alzheimer's Disease: Targeting Mitochondria for Diagnosis and Prevention.

Authors:  Yunhua Peng; Peipei Gao; Le Shi; Lei Chen; Jiankang Liu; Jiangang Long
Journal:  Antioxid Redox Signal       Date:  2020-03-16       Impact factor: 8.401

2.  Cystatin C is released in association with exosomes: a new tool of neuronal communication which is unbalanced in Alzheimer's disease.

Authors:  Roberta Ghidoni; Anna Paterlini; Valentina Albertini; Michela Glionna; Eugenio Monti; Luisa Schiaffonati; Luisa Benussi; Efrat Levy; Giuliano Binetti
Journal:  Neurobiol Aging       Date:  2009-09-20       Impact factor: 4.673

Review 3.  Understanding the roles of mutations in the amyloid precursor protein in Alzheimer disease.

Authors:  S Hunter; C Brayne
Journal:  Mol Psychiatry       Date:  2017-11-07       Impact factor: 15.992

4.  Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer's disease.

Authors:  Sascha Weggen; Dirk Beher
Journal:  Alzheimers Res Ther       Date:  2012-03-30       Impact factor: 6.982

Review 5.  A window into the heterogeneity of human cerebrospinal fluid Aβ peptides.

Authors:  Roberta Ghidoni; Anna Paterlini; Valentina Albertini; Elena Stoppani; Giuliano Binetti; Kjell Fuxe; Luisa Benussi; Luigi F Agnati
Journal:  J Biomed Biotechnol       Date:  2011-08-23

6.  γ-Secretase complexes containing caspase-cleaved presenilin-1 increase intracellular Aβ(42) /Aβ(40) ratio.

Authors:  Louise Hedskog; Camilla A Hansson Petersen; Annelie I Svensson; Hedvig Welander; Lars O Tjernberg; Helena Karlström; Maria Ankarcrona
Journal:  J Cell Mol Med       Date:  2011-10       Impact factor: 5.310

7.  Conformational targeting of intracellular Aβ oligomers demonstrates their pathological oligomerization inside the endoplasmic reticulum.

Authors:  Giovanni Meli; Agnese Lecci; Annalisa Manca; Nina Krako; Valentina Albertini; Luisa Benussi; Roberta Ghidoni; Antonino Cattaneo
Journal:  Nat Commun       Date:  2014-05-27       Impact factor: 14.919

8.  Methionine Oxidation Changes the Mechanism of Aβ Peptide Binding to the DMPC Bilayer.

Authors:  Christopher Lockhart; Amy K Smith; Dmitri K Klimov
Journal:  Sci Rep       Date:  2019-04-11       Impact factor: 4.379

9.  A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease.

Authors:  Michael Grundman; Roger Morgan; Jason D Lickliter; Lon S Schneider; Steven DeKosky; Nicholas J Izzo; Robert Guttendorf; Michelle Higgin; Julie Pribyl; Kelsie Mozzoni; Hank Safferstein; Susan M Catalano
Journal:  Alzheimers Dement (N Y)       Date:  2019-01-23

Review 10.  Early onset Alzheimer's disease and oxidative stress.

Authors:  Marco Antonio Meraz-Ríos; Diana Franco-Bocanegra; Danira Toral Rios; Victoria Campos-Peña
Journal:  Oxid Med Cell Longev       Date:  2014-01-14       Impact factor: 6.543

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.